Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)

NCT00734097 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00734097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00734097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2007
Completion date
October 31, 2008
Enrollment
314 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux disease